Clinical trial
Feasibility Study to Evaluate the Initial Safety and Effectiveness of TRUFILL n-BCA Liquid Embolic System in Middle Meningeal Artery Embolization for the Preventive Treatment of Refractory Chronic Migraine
NCT06735833 is registered in ClinicalTrials.gov with Cerenovus, Part of DePuy Synthes Products, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Feasibility Study to Evaluate the Initial Safety and Effectiveness of TRUFILL n-BCA Liquid Embolic System in Middle Meningeal Artery Embolization for the Preventive Treatment of Refractory Chronic Migraine
- Lead sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- April 23, 2025
- Completion date
- July 31, 2029
- Enrollment
- 70 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.